BPC-157 vs TB-500: Evidence and Safety

FDA’s TB-500 briefing identifies TB-500 free base as Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH, or LKKTETQ, a synthetic seven-amino-acid fragment from positions 17 through 23 of thymosin beta-4. FDA also reports inconsistent naming information in the nomination. Exact molecule identification is necessary before applying evidence.

Full-length thymosin beta-4 is a distinct 43-residue molecule. A study of recombinant full-length thymosin beta-4 or an ophthalmic formulation of it is not a study of LKKTETQ. Neither a parent molecule nor a fragment can be presumed to have the same exposure, activity, safety profile, or clinical effect. Here, TB-500 means the FDA-described LKKTETQ fragment.[2][5]

A BPC-157 phase I registry record describes an oral protocol in healthy volunteers, but it has an unknown status, an old update date, and no posted results. A 2025 intravenous report involved two adults and reported no side effects or measured biomarker changes during brief follow-up. It was not a controlled injury-recovery trial.

The registered BPC-157 rotator-cuff study is randomized and placebo-controlled in design, but was not yet recruiting and has no results. It does not show postoperative recovery, functional improvement, or safety. For TB-500 fragment, FDA found no medical-literature information in which it was administered to patients for any disease or condition, including wound healing. FDA also found no in-vivo pharmacology or toxicology studies of the evaluated free-base or acetate forms that could support the nominated wound-healing use.[2][3][4][11]

Human full-length thymosin beta-4 research provides a boundary, not proof for TB-500 fragment. A phase I study tested recombinant human thymosin beta-4 in 54 healthy volunteers after a single intravenous administration and 30 after repeated administration. It reported mild-to-moderate adverse events, with no dose-limiting toxicities or serious adverse events during that study. This is short-term safety information for the full-length molecule in selected healthy participants.

A nine-participant eye-drop trial of full-length thymosin beta-4 reported eye-specific dry-eye outcomes and no adverse events in its small safety population. A completed 699-participant dry-eye trial used a preservative-free ophthalmic solution containing thymosin beta-4. These topical dry-eye studies do not establish that TB-500 fragment treats physical injuries or that either substance improves general recovery.[5][6][7]

The absence of reported harm in a very small, short study does not establish broad safety. FDA says compounded BPC-157 may present immunogenicity and peptide-characterization concerns and that safety information is absent or limited for proposed routes. For TB-500 fragment, FDA cites absent human exposure data and possible immunogenicity related to aggregation and peptide-related impurities. These statements identify uncertainty; they do not quantify an individual risk.

A ClinicalTrials.gov query matching BPC-157 and TB-500 returned zero records on the review date. It cannot exclude unpublished work, alternative terminology, or studies outside that registry. It does mean that this search supplies no registered human trial support for synergy, faster healing, or a safer combined approach. For athletes governed by WADA rules, BPC-157 is specifically listed in S0 and prohibited at all times.[1][2][8][10]